New antibody tackles stubborn biofilms in cystic fibrosis lungs
Disease control
Completed
This study tested a single dose of CMTX-101, an antibody designed to break up bacterial biofilms, in 43 adults with cystic fibrosis who have chronic lung infections with Pseudomonas aeruginosa. The goal was to see if adding CMTX-101 to standard inhaled antibiotics is safe and tol…
Phase: PHASE1, PHASE2 • Sponsor: Clarametyx Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC